Our top pick for
AtriCure, Inc is a medical instruments & supplies business based in the US. AtriCure shares (ATRC) are listed on the NASDAQ and all prices are listed in US Dollars. AtriCure employs 730 staff and has a trailing 12-month revenue of around USD$212 million.
Since the stock market crash in March caused by coronavirus, AtriCure's share price has had significant positive movement.
Its last market close was USD$40.7, which is 3.17% up on its pre-crash value of USD$39.41 and 75.70% up on the lowest point reached during the March crash when the shares fell as low as USD$23.165.
If you had bought USD$1,000 worth of AtriCure shares at the start of February 2020, those shares would have been worth USD$679.60 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$1,052.91.
|Latest market close||USD$40.7|
|52-week range||USD$23.165 - USD$51.76|
|50-day moving average||USD$40.738|
|200-day moving average||USD$42.8283|
|Wall St. target price||USD$55.63|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.565|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-20)||-4.15%|
|1 month (2020-10-30)||17.77%|
|3 months (2020-08-28)||-4.28%|
|6 months (2020-05-29)||-14.87%|
|1 year (2019-11-29)||36.81%|
|2 years (2018-11-29)||22.59%|
|3 years (2017-11-29)||121.44%|
|5 years (2015-11-27)||81.62%|
|Revenue TTM||USD$212 million|
|Gross profit TTM||USD$170.3 million|
|Return on assets TTM||-5.83%|
|Return on equity TTM||-15.22%|
|Market capitalisation||USD$1.8 billion|
TTM: trailing 12 months
There are currently 2.2 million AtriCure shares held short by investors – that's known as AtriCure's "short interest". This figure is 18.5% up from 1.9 million last month.
There are a few different ways that this level of interest in shorting AtriCure shares can be evaluated.
AtriCure's "short interest ratio" (SIR) is the quantity of AtriCure shares currently shorted divided by the average quantity of AtriCure shares traded daily (recently around 351686.14173228). AtriCure's SIR currently stands at 6.35. In other words for every 100,000 AtriCure shares traded daily on the market, roughly 6350 shares are currently held short.
However AtriCure's short interest can also be evaluated against the total number of AtriCure shares, or, against the total number of tradable AtriCure shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case AtriCure's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 AtriCure shares in existence, roughly 50 shares are currently held short) or 0.0595% of the tradable shares (for every 100,000 tradable AtriCure shares, roughly 60 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against AtriCure.
Find out more about how you can short AtriCure stock.
We're not expecting AtriCure to pay a dividend over the next 12 months.
Over the last 12 months, AtriCure's shares have ranged in value from as little as $23.165 up to $51.76. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while AtriCure's is 0.717. This would suggest that AtriCure's shares are less volatile than average (for this exchange).
AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems to medical centers in the United States and internationally. The company offers Isolator Synergy and Isolator Synergy Access clamps for the treatment of persistent and long-standing persistent atrial fibrillation concomitant to other open-heart surgical procedures; EPi-Sense guided coagulation system used for the coagulation of tissue; and COBRA Fusion surgical ablation system to combine bipolar temperature-controlled radio frequency energy control with monopolar energy. It also provides multifunctional pens that allow surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and linear ablation devices, which enable users to make longer linear lines of ablation. In addition, the company offers cryoICE cryoablation system used to ablate cardiac tissue for the treatment of cardiac arrhythmias; AtriClip system used to occlude the left atrial appendage by mechanically clamping the appendage; and CryoICE CRYO2 cryoablation system to apply cryo-energy to targeted intercostal peripheral nerves in the ribcage and temporarily relieve pain. Further, it provides Lumitip dissector to separate tissues to provide access to key anatomical structures that are targeted for ablation; Fusion Magnetic Retriever System that allows access around anatomical structures; and cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. The company sells its products through independent distributors and direct sales personnel. The company was founded in 2000 and is headquartered in Mason, Ohio.
Steps to owning and managing CCF, with 24-hour and historical pricing before you buy.
Steps to owning and managing CDW, with 24-hour and historical pricing before you buy.
Steps to owning and managing CWH, with 24-hour and historical pricing before you buy.
Steps to owning and managing CBIO, with 24-hour and historical pricing before you buy.
Steps to owning and managing BLIN, with 24-hour and historical pricing before you buy.
Steps to owning and managing CVGW, with 24-hour and historical pricing before you buy.
Steps to owning and managing AEGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing AJG, with 24-hour and historical pricing before you buy.
Steps to owning and managing ABB, with 24-hour and historical pricing before you buy.
Steps to owning and managing YGYI, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.